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C L I N I C A L R E S E A R C H A R T I C L E
The Effect of a Subcutaneous Infusion of GLP-1, OXM,
and PYY on Energy Intake and Expenditure
in Obese Volunteers
Tricia Tan,1 Preeshila Behary,1 George Tharakan,1 James Minnion,1 Werd Al-Najim,1
Nicolai J. Wewer Albrechtsen,2 Jens J. Holst,2 and Stephen R. Bloom1
1Division of Diabetes, Endocrinology, and Metabolism, Hammersmith Hospital, Imperial College London,
London W12 0HS, United Kingdom; and 2Department of Biochemical Sciences and Novo Nordisk
Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of
Copenhagen, DK-2200 Copenhagen, Denmark
Background: Roux-en-Y gastric bypass (RYGB) surgery is currently the most effective treatment of
obesity, although limited by availability and operative risk. The gut hormones Glucagon-like
peptide-1 (GLP-1), Peptide YY (PYY), and Oxyntomodulin (OXM) are elevated postprandially
after RYGB, which has been postulated to contribute to its metabolic benefits.
Objective: We hypothesized that infusion of the three gut hormones to achieve levels similar to
those encountered postprandially in RYGB patients might be effective in suppressing appetite. The
aim of this study was to investigate the effect of a continuous infusion of GLP-1, OXM, and PYY
(GOP) on energy intake and expenditure in obese volunteers.
Methods: Obese volunteers were randomized to receive an infusion of GOP or placebo in a single-
blinded, randomized, placebo-controlled crossover study for 10.5 hours a day. This was delivered
subcutaneously using a pump device, allowing volunteers to remain ambulatory. Ad libitum food
intake studies were performed during the infusion, and energy expenditure was measured using a
ventilated hood calorimeter.
Results: Postprandial levels of GLP-1, OXM, and PYY seen post RYGB were successfully matched using
4 pmol/kg/min, 4 pmol/kg/min, and 0.4 pmol/kg/min, respectively. This dose led to a mean reduction of
32% in food intake. No significant effects on resting energy expenditure were observed.
Conclusion: This is, to our knowledge, the first time that an acute continuous subcutaneous infusion
of GOP, replicating the postprandial levels observed after RYGB, is shown to be safe and effective in
reducing food intake. This data suggests that triple hormone therapy might be a useful tool
against obesity. (J Clin Endocrinol Metab 102: 2364–2372, 2017)
Obesity affects a quarter of the UK population, andat least a third of the world population is considered
overweight or obese (1, 2). Bariatric surgery is currently
the most effective treatment of obesity and related con-
ditions such as type 2 diabetes (3, 4). Glucagon-like
peptide-1 (GLP-1), Oxyntomodulin (OXM), and Peptide
YY (PYY) are anorexia-inducing hormones secreted from
the neuroendocrine L cells of the gut in response to nu-
trients (5–7).GLP-1 is also known to be insulinotropic, and
OXM has the potential to increase energy expenditure (8).
Postprandial secretion of the gut hormones GLP-1, OXM,
and PYY is dramatically elevated after Roux-en-Y gastric
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bypass (RYGB) (7, 9, 10). It has been hypothesized that
these hormonal changes importantly contribute to the
significant and sustained weight loss observed post RYGB
surgery (11, 12).
Intravenous infusion or subcutaneous injectionof eachof
the individual three hormones at slightly higher concen-
trations has been shown to cause modest reductions in ad
libitum food intake in humans (8, 13, 14). Studies involving
intravenous coinfusion of PYY and GLP-1, or GLP-1 and
OXM, demonstrated both additive and synergistic effects
on food intake reduction (15–19). These studies suggest that
both a single and dual combination of gut hormones are
effective in reducing energy intake. In this study, a combi-
nation of GLP-1, OXM, and PYY (GOP) was administered
to obese volunteers in a single-blinded, placebo-controlled
study with a crossover design. The aim was to (1) replicate
the observed postprandial levels of GLP-1, OXM, and PYY
after RYGB, (2) assess the safety and tolerability of theGOP
combination infusion, and (3) assess the effect of GOP
on food intake and resting energy expenditure (REE). To
achieve this in an ambulatory setting, GOP was infused
continuously using a subcutaneous pump device. We con-
ducted an initial dose-finding study in which we identified
the doses of each peptide, which would simulate the post-
prandial RYGB milieu when infused in combination.
This study was also designed in anticipation of future
studies in which volunteers might be wearing the pump
in a free-living environment for 1 to 3 months. Contin-
uous subcutaneous infusion of GLP-1 between 48 hours
and 3 months has been described before. The majority of
these studies demonstrated a significant improvement in
glycemic parameters in overweight and obese volunteers
with diabetes while demonstrating that the technique was
safe and practical (20–23).
Methods
Participants
The study was designed as a randomized, single-blinded,
placebo-controlled study with crossover arms. The study took
place at the National Institute for Health Research/Wellcome
Trust Clinical Research Unit Facility at HammersmithHospital.
Ethical approval was obtained from the West London National
Research Ethics Committee (reference number 13/LO/1510),
and the study was conducted according to the principles of the
Declaration of Helsinki. Obese healthy volunteers, between
ages 18 and 65 years, with a body mass index (BMI) of over
30 kg/m2 were recruited for the infusion study. Volunteers were
excluded if they were smokers (as this suppresses appetite) or
possessed a history of a eating disorder as assessed by the
SCOFF and Dutch Eating Behavior Questionnaires (24, 25).
Study protocol
Participants attended the research unit in the fasted state at
8 AMon day 1 for a 3-day inpatient study visit. The study protocol
is shown in Fig. 1. Day 1 consisted of a positive acclimatization
visit whereby all volunteers received a lower dose GOP infusion
(see below) to limit the effects of stress caused by subjects being
unfamiliar with study procedures. A venous cannula was
inserted in the antecubital fossa, and samples were taken for gut
hormones, glucose, and insulin levels at the start of the sub-
cutaneous pump infusion and subsequently at 1, 2, 4, 6, 8,
and 10 hours. Visual analog scores (VASs) for sensations of
“sickness,” “hunger,” “amount to eat,” and “fullness,” as well
as pulse rate and blood pressure, were also recorded (26). A
cannula attached to the infusion pump was positioned in the
abdominal subcutis allowing for a 10.5-hour infusion. The
pump was stopped after dinner. On day 2, volunteers were
randomized in a single-blinded fashion to receive either GOP or
0.9% saline for 10.5 hours following the same protocol as on
day 1. On day 3, the volunteers were given either GOP or 0.9%
saline infusion, whichever had not been given on day 2.
RYGB cohort
A separate surgical study cohort who had RYGB surgery at
Imperial Weight Centre between 2007 and 2012 was also
recruited for measurement of the reference gut hormone levels
we would be targeting in our infusion study. The RYGB vol-
unteers arrived at the unit at 9 AM in the fasted state. A stan-
dardized mixed meal test (Ensure Plus; Abbott, Maidenhead,
United Kingdom; 13.8 g of protein, 10.8 g of fat, 44.4 g of
carbohydrates, 330 kcal, 220 mL) was given, and volunteers
were directed to drink the Ensure Plus over 10 minutes. Blood
was taken from an indwelling cannula placed in the antecubital
fossa for gut hormone (GLP-1, OXM, and PYY), glucose, and
insulin measurement at baseline and 30, 60, and 120 minutes
post Ensure Plus ingestion.
GOP infusion and doses
GLP-1 (7-36) amide, PYY (3-36), andOXMwere purchased
from Insight Biotechnology (London, United Kingdom). The
freeze-dried peptides were reconstituted in saline and were
shown to be stable for up to 12 hours at 37°C, as assessed by
high-performance liquid chromatography. We changed the
infusion to a freshly constituted solution after 8 hours on every
studyday to assure that the infusedpeptideswere active.Aportable
Cane Crono infusion pump (Applied Medical Technology,
Cambridge, United Kingdom) was used to deliver the peptides
subcutaneously via an infusion set inserted under the anterior
abdominal skin (Quick-set Infusion Set; Medtronic, Watford,
United Kingdom). Gelofusine was used to prime the syringes and
tubing prior to use to prevent adsorption of the peptides to tubing
(27); however, the peptides were reconstituted in 0.9% saline for
subcutaneous infusion. Following an initial dose-finding study, in
which individual peptides were given for periods of up to 10 hours
to volunteers to determine the steady-state plasma levels, we found
that a combination of GLP-1 at 4 pmol/kg/min, OXM at 4 pmol/
kg/min, and PYY at 0.4 pmol/kg/min was able to replicate the
postprandial levels seen after RYGB. On day 2 or 3, these were
given continuously for 10.5 hours. For the acclimatization visit on
day 1, we started the infusion at a lower dose of 3 pmol/kg/min of
both GLP-1 and OXM and 0.3 pmol/kg/min of PYY.
Ad libitum food intake
Ad libitum food intake studies were performed at 4 and
10 hours during the infusion on each study day. A choice
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of homogenized meals of similar calorie density was served
(Sainsbury’s Supermarkets Ltd, London, United Kingdom).
Meal choices were served to volunteers at the screening
visit, and volunteers were asked to rate their preference for
each choice. Where volunteers recorded a dislike or ex-
treme preference for a specific meal choice, these were
excluded from their menu for the study days to minimize
bias. Similar meals were served on study days 2 and 3 for
direct comparison. Volunteers were asked to eat until
comfortably full.
Energy expenditure
Indirect calorimetry carried out with a ventilated hood
system (Gas Exchange Monitor; GEM Nutrition, Daresbury,
United Kingdom) was used to measure REE (19). Energy ex-
penditure at baseline (prior to infusion start) and following
3.5 hours of GOP infusion or 0.9% saline (fasted state) was
measured on each study day. Volunteers emptied their bladder
prior to the baseline calorimeter, and urine was collected at
the end of the second calorimeter for estimation of urinary
nitrogen. Volunteers were asked to relax in the semisupine
position for 30minutes before each calorimeter recording. The





CO2, respectively, were measured every minute, and
estimation of energy expenditure was performed following the
abbreviated Weir equation, with adjustment for urinary ni-
trogen excretion. Readings were taken for 15 to 20 minutes,
allowing at least 10 minutes for the readings to stabilize. The
mean of the five most stable, consecutive measurements was
used in the analysis.
Assays
Blood samples for gut hormone analysis were collected in
lithium heparin collection tubes containing 0.1 mL of aprotinin
for every 4 mL of blood. After centrifugation, plasma
was stored at –80°C until analysis. Active GLP-1 and total
PYY were measured by the MILLIPLEX
magnetic bead–based multianalyte, me-
tabolic panel, four-plex immunoassay
(Millipore, St. Charles, MO), which was
selective for the individual analyte. The
intra-assay and interassay coefficient of
variation for each analyte was ,10%, and
the lowest limit of detection for each pep-
tide was 0.8 and 3.4 pmol/L for active GLP-
1 and total PYY, respectively. OXM was
measured using a specific and sensitive
mass spectrometry validated assay (Holst
Laboratory, University of Copenhagen,
Copenhagen, Denmark) (7). Intra- and interassay precision
(% CV) for the OXM assay was ,10%.
Statistical analysis
All analyses were carried out and figures produced using
GraphPad Prism 6 (GraphPad Software, San Diego, CA). De-
scriptive data are expressed as the mean6 the standard error of
the mean (SEM). A paired Student t test was used to compare
food intake and energy expenditure between GOP and 0.9%
saline infusion. Two-way repeated-measures analysis of variance
(ANOVA) with a Bonferroni post hoc test was used to compare
safety parameters and VASs across the two infusions, and one-
wayANOVAwith a Tukey post hoc test was used to compare gut
hormone levels between the infusions and RYGB group.
The area under the curve (AUC) for glucose and insulin was
calculated using the trapezoid rule, and comparison between
GOP and 0.9% saline arms was made using the paired Student
t test. The effect size was estimated using food intake data from
pilot studies in our department. Using a significance level of 5%
and a power of 80%, we estimated that 10 volunteers were
sufficient to demonstrate a food reduction of 30% with GOP
compared with 0.9% saline.
Results
Ten volunteers were recruited for the infusion study
(infusion group), and 8 volunteers who were 3 6 0.6
years post RYGB were studied as the reference group
(RYGB group). The two groups were matched for age and
BMI (Table 1). None of the volunteers had diabetes at the
time of the study, although one volunteer in the infusion
group had impaired fasting glucose according to American
Diabetes Association criteria. All volunteers in the surgical
group achieved successful and stable weight loss of
Figure 1. Study protocol.
Table 1. Demographics of Infusion Group and RYGB Group
Infusion (n = 10) RYGB (n = 8) P Value
Female:male 7:3 5:3
Age (years) 45.0 6 11 46.6 6 9.8 0.75
Weight (kg) 104.8 6 22.9 88.8 6 18.1 0.13
BMI (kg/m2) 36.3 6 5.6 34.8 6 4.9 0.65
HbA1c (%) (mmol/mol) 5.5 (36.3 6 5.4) 5.5 (36.7 6 3.1) 0.86
Data expressed as mean 6 standard deviation.
Abbreviation: HbA1c, glycated hemoglobin.
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32.2% 6 11.9% (mean 6 standard deviation) at the
time of the study, and four had diabetes prior to RYGB.
Food intake and VAS
All volunteers ate less when GOP was infused (Fig. 2).
Volunteers consumed 468.36 73.8 kcal for lunch during
GOP infusion vs 645 6 55.9 kcal on 0.9% saline (P =
0.04). Food consumption for dinner was 4206 90.6 kcal
during GOP infusion vs 664.7 6 83.5 kcal on 0.9%
saline (P = 0.005). Total food intake over 10 hours of
infusion was thus significantly lower on GOP compared
with 0.9% saline (888.96 89.3 kcal vs 1310 6 127 kcal,
respectively; P = 0.0005). This represents a mean reduction
of total food intake of 32% or 421.1 kcal. There was no
significant difference in the food intake reduction when the
volunteers who had 0.9% saline first were compared with
those who had GOP infusion first (Supplemental Table 1).
Three volunteers experienced mild nausea with GOP,
which eventually settledwithout requiring any intervention
within the first 2 to 4 hours of the infusion, and none with
0.9% saline infusion. However, there was statistically no
significant difference between nausea scores as recorded on
VASs between the two infusions. Sensations of “hunger,”
“amount to eat,” and “fullness” scores were also not
significantly different (Fig. 3).
GOP blood levels
The circulating levels ofGOPachieved on4pmol/kg/min
of GLP-1, 4 pmol/kg/min of OXM, and 0.4 pmol/kg/min of
PYY infused subcutaneously over 10.5 hours are shown
in Fig. 4. Baseline levels of GLP-1 were comparable be-
tween all three groups (GOP arm: 3.5 6 0.6 pmol/L;
RYGB group: 4.36 1.2 pmol/L; 0.9% saline arm: 3.56
0.6 pmol/L; P = 0.78 for comparison between GOP arm
and RYGB group and P = 1.0 for comparison between
GOP arm and 0.9% saline arm) and similarly for baseline
PYY (GOP arm: 26.3 6 4.0 pmol/L; RYGB group:
21.6 6 4.2 pmol/L; 0.9% saline: 28.3 6 3.6 pmol/L; P =
0.70 for comparison betweenGOP arm andRYGB group
and P = 0.93 for comparison between GOP arm and
0.9% saline arm). Baseline OXM levels were non-
significantly lower in the RYGB group compared with
GOP (RYGB group: 10.5 6 1.7 pmol/L vs GOP arm:
15.86 2.3 pmol/L; P = 0.2) and comparable between the
GOP and 0.9% saline arms (0.9% saline arm: 16.2 6
2.3 pmol/L; P = 0.99). As expected, the RYGB group
showed at least a fourfold increase in postprandial levels
of each peptide following a standardizedmixedmeal. The
peak postprandial levels of each hormone in the RYGB
group closely matched the peak levels achieved by GOP
infusion (RYGB vs GOP, respectively: GLP-1: 26.3 6
3.5 pmol/L vs 26.16 3.2 pmol/L, P = 1.0; OXM: 94.36
10.5 pmol/L vs 83.8 6 6.8 pmol/L, P = 0.56; PYY:
81.3 6 17.8 pmol/L vs 79.2 6 11.2 pmol/L, P = 0.99).
These levels were achieved within 4 hours of starting the
infusion. As expected, peak GLP-1, OXM, and PYY levels
in the 0.9% saline infusion arm were significantly lower
compared with the RYGB and GOP groups (0.9% saline
GLP-1: 7.0 6 1.4 pmol/L, P , 0.0001 compared with
GOP and P , 0.001 compared with RYGB; 0.9% saline
OXM: 24.6 6 3.0 pmol/L, P , 0.0001 compared with
GOP and P, 0.0001 compared with RYGB; 0.9% saline
PYY: 28.9 6 3.6 pmol/L, P , 0.01 compared with GOP
and P , 0.05 compared with RYGB).
Energy expenditure
REE was measured in seven volunteers. The change in
REE between baseline and infusion phases was not sig-
nificantly different betweenGOPand0.9%saline infusions
(–4.66 74.2 kcal/24 h vs 22.06 68.8 kcal/24 h, P = 0.78).
Safety parameters
We observed no significant difference in systolic and
diastolic blood pressure profiles as well as pulse rate
Figure 2. Food intake on GOP vs 0.9% saline (n = 10). (a) Food intake at lunch, dinner, and lunch plus dinner as measured on the GOP infusion
day, compared with the 0.9% saline infusion day. Lunch and dinner served at t = 4 and t =10 hours, respectively. Mean 6 SEM plotted. Paired
Student t test shows significant differences between saline and GOP arms for lunch, dinner, and total (lunch plus dinner) food intake. (b)
Individual total food intake on GOP vs 0.9% saline infusion.
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between GOP and 0.9% saline infusion (Supplemental
Fig. 1). Mean fasting glucose was 5.9 6 0.4 mmol/L
and 5.7 6 0.3 mmol/L and mean fasting insulin was
13.4 6 1.9 mIU/L and 13.9 6 1.3 mIU/L on GOP and
0.9% saline infusion days, respectively. During the first
4 hours of the infusion (fasted state), glucose levels were
comparable between both arms. However, by 6 hours
(2 hours after lunch), glucose levels diverged and were
significantly higher in the 0.9%saline arm (5.260.3mmol/L
vs 6.0 6 0.3 mmol/L, P , 0.001). Insulin levels also
followed a similar pattern. Fasting insulin levels were
comparable during the first 4 hours of the infusion in
Figure 4. GLP-1, OXM, and PYY levels achieved following GOP and 0.9% saline infusion. (a) GLP-1 levels. Peak postprandial levels of GLP-1 in
RYGB group matched by GOP infusion. (b) OXM levels. Peak postprandial levels of OXM in RYGB matched by GOP infusion. (c) Total PYY levels.
Peak postprandial levels of PYY in RYGB matched by GOP infusion.
Figure 3. Change in VASs between GOP (dashed line, triangle symbols) and 0.9% saline (solid line, square symbols) infusion. Mean 6 SEM
plotted. (a) “How sick do you feel?” score. (b) “How hungry do you feel?” score. (c) “How much can you eat?” score. (d) “How full do you
feel?” score. No significant differences observed between the two infusions on two-way repeated-measures ANOVA with Bonferroni post hoc test.
2368 Tan et al GOP Infusion and Energy Intake J Clin Endocrinol Metab, July 2017, 102(7):2364–2372
Downloaded from https://academic.oup.com/jcem/article-abstract/102/7/2364/3100443
by Kobenhavns Universitets user
on 09 March 2018
both arms, but by 6 hours, insulin levels were signifi-
cantly higher in the 0.9% saline arm (24.36 4.6 mIU/L
vs 43.3 6 6.7 mIU/L, P , 0.001; Fig. 5). Importantly,
there was no episode of hypoglycemia in either in-
fusion arm.
Discussion
We have demonstrated that a continuous subcutaneous
infusion of the peptides GLP-1, OXM, and PYY can be
safely and successfully given to obese, nondiabetic vol-
unteers in an ambulatory setting. Using doses of 4 pmol/
kg/min of GLP-1, 4 pmol/kg/min of OXM, and 0.4 pmol/
kg/min of PYY, wewere able to reach target levels of each
hormone comparable to the postprandial levels observed
in our BMI-matched RYGB cohort. As expected, with
subcutaneous delivery, it took longer to achieve stable
levels in comparison with intravenous infusions in pre-
vious studies (13, 28–30), but these levels were stably
maintained for several hours in ambulatory patients.
Previous studies have infused subcutaneous GLP-1 at
doses between 1.2 pmol/kg/min and 8.5 pmol/kg/min (21,
22). Toft-Nielsen et al. achievedmean active GLP-1 levels
of 22.5 6 3.7 pmol/L following a dose of 2.4 pmol/kg/
min, which is comparable to what we measured on
4 pmol/kg/min (26.1 6 3.2 pmol/L) (20). This disparity
in doses is likely to be due to differences in study protocol
and methods: They infused only GLP-1 continuously
for a longer period of 48 hours, and therewere differences
in the assays used.
Energy intake was reduced by 32% during 10.5 hours
of GOP infusion compared with 0.9% saline. During our
initial dose finding with infusions of individual peptides,
we found that subcutaneous infusion doses of 12 pmol/
kg/min for GLP-1, 30 pmol/kg/min for OXM, and
1 pmol/kg/min for PYY, respectively, were necessary to
achieve comparable food intake reductions of 21% to
37% (Supplemental Fig. 2). In other words, when
combined, the three peptides achieved a profound food
intake reduction with much reduced doses. The food
intake reduction observed in the current study is also in
keeping with other combination intravenous infusion
studies; for example, De Silva et al. and Schmidt et al.
both found a reduction of 27% and 30% in food intake,
respectively, when GLP-1 and PYY were infused in
combination (15, 16), and Field et al. infused OXM and
GLP-1 in combination, which resulted in a similar re-
duction in food intake (18). The key differences between
the current study and these previous studies are as fol-
lows: (1) This is, to our knowledge, the first time that such
effects have been demonstrated with continuous sub-
cutaneous infusion of a triple combination of GLP-1,
OXM, and PYY at circulating levels comparable to those
observed postprandially in RYGB patients, as opposed to
the more elevated levels seen in previous infusion studies;
(2) this study used an infusion over an extended period
of time (10.5 hours) compared with previous studies
employing shorter durations of 120 to 150 minutes (15,
16), indicating that this can potentially be given chron-
ically for a sustained effect on energy intake and sub-
sequent weight loss; and (3) the volunteers were fully
ambulatory during the infusion, which is more in keeping
with a “free-living” setting.
GLP-1 and PYY are known to have powerful anorexic
effects by binding to GLP-1 and Neuropeptide Y2 re-
ceptors, respectively, located mainly within the hypo-
thalamus in studies in rodents and humans (5, 6, 31).
However, OXM is believed to exert its anorexic effects
via the GLP-1 and Glucagon receptors, albeit it has a
much lower binding affinity for these receptors compared
with their cognate peptides. GLP-1 and PYY are likely to
be the main contributors toward the reduction in food
intake observed in our study. Our current study was not
designed to disentangle the contribution of each peptide
toward the reduction in energy intake observed nor to
assess any additive or synergistic effects of a triple-
hormone infusion but rather to investigate the effects
of a postprandial RYGB hormonal milieu on energy
intake in a nonsurgical cohort. Nevertheless, the re-
duction in energy intake observed in our study, if sus-
tained long term, could contribute to greater magnitudes
of weight loss compared to current therapies where
weight loss of up to 10% is typically achieved (32–35).
We did not find any statistically significant change in
REE following GOP infusion at the doses used in this
study, consistent with the study of Bagger et al., who
showed that IV infusions of GLP-1 and OXM do not
change REE as assessed by calorimetry (36). Limitations
with respect to this observation include the fact that our
study was not specifically powered for this outcome and
the study design did not allow for measurement of REE
beyond 4 hours of the infusion, as volunteers were then
fed. Although OXM has been shown to induce an in-
crease in activity-related energy expenditure following
subcutaneous injection (8), the protocol did not measure
this specific aspect of energy expenditure.
Three out of 10 volunteers experienced mild nausea
during the first 2 to 4 hours of the GOP infusion. The
nausea spontaneously resolved, and volunteers remained
free of nausea for the remaining part of the infusion. The
nausea observed in our study is unlikely to have influ-
enced food intake, as has previously been found with
GLP-1 analogs, and statistically, there was no significant
difference between the VASs for “sickness” on GOP
compared with 0.9% saline. In addition, none of the
volunteers experienced any nausea during the latter
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6 hours of the infusion, and food intake at both lunch and
dinner were reduced equally by about a third. Volunteers
receiving GOP tended to be less “hungry” during the first
4 hours of the infusion, although this did not reach
statistical significance.
There was no safety concern in relation to hemody-
namic parameters during GOP infusion. Subcutaneous
GLP-1, at 2.4 pmol/kg/min, has previously been shown
to slightly lower blood pressure possibly through re-
laxation of the vasculature and through diuresis (20).
However, we did not observe a significant change in
blood pressure.
We did not observe any significant reductions in
glucose or insulin secretion enhancement with GOP
compared with the 0.9% saline arm. This may be
explained by the fact that our volunteers did not have
diabetes, and that GLP-1’s insulinotropic effects are
glucose level dependent. In the postprandial state, vol-
unteers on 0.9% saline displayed a significantly higher
glucose and insulin response following lunch at 6 hours;
this is likely to be related to increased consumption of the
test meal compared with the GOP arm. Delayed gastric
emptying in volunteers receiving GOP may also be a
contributing factor to these observed differences between
the two groups. In contrast, significant improvement
in glycemia, including insulin sensitivity, was observed
duringGLP-1 subcutaneous infusion in patientswith type
2 diabetes (21, 22).
Some limitations to this study should be noted,
including a relatively small sample size (which was
powered to detect a significant difference in food intake)
and the single-blinded design. The continuous infusion of
GOP does not reflect the patterns of peaks and troughs of
gut hormones seen after RYGB. The postprandial ele-
vation in gut hormones usually peaks around 30 minutes
after ingestionwith levels returning to baseline by 3 hours
(11). We chose not to give a bolus of GOP with meals
because a rapid rise in circulating levels is more likely to
induce nausea. Furthermore, RYGB patients tend to have
smaller but more frequent meals (five to six a day), thus
experiencing regular elevations in gut hormone secretion
(37). This leads to a very similar overall exposure to
elevated levels of gut hormones between RYGB and our
current GOP infusion.
In conclusion, our findings suggest that the post-
prandial elevations in GLP-1, OXM, and PYY observed
after RYGB can be recapitulated with a subcutaneous
triple-hormone infusion, leading to a profound reduction
Figure 5. The effects of GOP (dashed line, triangle symbols) and 0.9% saline infusion (solid line, square symbols) on glucose and insulin profile.
(a) Glucose levels at 6 hours significantly higher on 0.9% saline infusion. (b) Insulin levels at 6 hours significantly higher on 0.9% saline infusion.
Mean 6 SEM plotted with two-way repeated-measures ANOVA with Bonferroni post hoc test: ***P , 0.001. (c and d) No significant difference
observed between glucose and insulin AUCs over the first 4 hours. Paired Student t test applied to compare AUCs calculated for glucose and
insulin over the first 4 hours of infusion (fasted state).
2370 Tan et al GOP Infusion and Energy Intake J Clin Endocrinol Metab, July 2017, 102(7):2364–2372
Downloaded from https://academic.oup.com/jcem/article-abstract/102/7/2364/3100443
by Kobenhavns Universitets user
on 09 March 2018
of food intake. We also speculate that this could be
exploited in future treatments for obesity and diabetes.
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